52 unknown. 52 Phase 2, 10 Phase 3, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 52 | Unknown 52 |
| Phase 3 | 10 | Unknown 10 |
| Phase 1 | 9 | Unknown 9 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparative Study Between Dexmedetomidine Versus Methylprednisolone on Induced Inflammatory Response in Patients Undergoing On-pump CABG Normal saline, Dexmedetomidine, Methylprednisolone - Coronary Artery Disease, Systemic Inflammatory Response Syndrome | Phase 1 / Phase 2 | Unknown | Ain Shams University | 60 | 2025-09-01 | 2025-08-06 |
| MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients MRG-001 (Low-dose), MRG-001 (High-dose), Placebo - Acute Respiratory Distress Syndrome, Respiratory Failure | Phase 2 | Unknown | MedRegen LLC | 60 | 2024-12-01 | 2024-08-23 |
| Studying Topiramate for Re-Activating the HIV-1 Reservoir Topiramate - HIV-1-infection, Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 12 | 2024-09-01 | 2024-02-28 |
| Early Resuscitation in Paediatric Sepsis Using Inotropes Fluid, Adrenalin - Sepsis | Phase 2 | Unknown | NATALIA LOPERA MUNERA | 40 | 2024-07-01 | 2024-06-27 |
| Dexmedetomidine and Vasopressin in Septic Shock DEX-PRESSIN, Standard of Care - Sepsis, Septic Shock | Phase 2 | Unknown | Mansoura University | 260 | 2024-06-01 | 2024-03-12 |
| REMAP ECMO - Beta Receptor Modulation Trial Esmolol - Heart Failure, Cardiogenic Shock | Phase 2 | Unknown | Erasmus Medical Center | 20 | 2024-06-01 | 2024-07-26 |
| Optimizing Reversal of HIV Latency With Combination Therapy Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule - Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 49 | 2024-04-01 | 2024-02-05 |
| Early Versus Conventional Cessation of Hydrocortisone in Septic Shock normal saline solution, Hydrocortisone and normal saline solution - Septic Shock, Adverse Event | Phase 2 | Unknown | Mahidol University | 160 | 2023-07-05 | 2024-04-05 |
| 101-PGC-005 for the Treatment of COVID-19 101-PGC-005, Dexamethasone - COVID-19 | Phase 2 | Unknown | 101 Therapeutics | 62 | 2023-01-31 | 2023-05-30 |
| The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock Ondansetron, Placebo - Sepsis, Septic Shock | Phase 1 / Phase 2 | Unknown | Noha Mansour | 40 | 2022-04-24 | 2023-03-15 |
| Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment Treatment-specific InSight, InSight - Sepsis, Severe Sepsis | Phase 2 | Unknown | Dascena | 51645 | 2022-04-01 | 2021-09-23 |
| Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease Lactoferrin (Apolactoferrin), Placebo of excipient(s) will be administered - Corona Virus Infection, Middle East Respiratory Syndrome (MERS) | Phase 2 | Unknown | National Research Centre, Egypt | 516 | 2022-02-01 | 2021-11-15 |
| Milrinone Versus Placebo in Patients With Septic Shock Milrinone - Septic Shock, Cardiac Output | Phase 2 | Unknown | Mahidol University | 64 | 2021-12-01 | 2022-09-15 |
| Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Basiliximab Injection, Placebo - SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection | Phase 2 | Unknown | Fort Worth Clinical Sciences Working Group | 300 | 2021-10-15 | 2021-08-19 |
| Machine Learning Sepsis Alert Notification Using Clinical Data HindSight, InSight - Sepsis, Severe Sepsis | Phase 2 | Unknown | Dascena | 37986 | 2021-09-25 | 2022-05-03 |
| Evaluation of Safety and Dosing of a Vitamin C Bundle for Sepsis Treatment in Africa Vitamin C, Vitamin B1 - Sepsis, Septic Shock | Phase 2 | Unknown | Liverpool School of Tropical Medicine | 60 | 2021-09-01 | 2021-09-08 |
| Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients. Selenium (as Selenious Acid), Placebo - Covid19 | Phase 2 | Unknown | CHRISTUS Health | 100 | 2021-08-15 | 2021-08-03 |
| Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients Exosome-MSC Intravenous injection, Placebo Intravenous Injection, COVID-19 Standard Treatment - SARS-CoV2 Infection | Phase 2 / Phase 3 | Unknown | Dermama Bioteknologi Laboratorium | 60 | 2021-07-01 | 2022-02-18 |
| Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome Cyclosporine - Stem Cell Transplant Complications, Cytokine Release Syndrome | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 32 | 2021-03-25 | 2021-03-05 |
| Prehospital Kcentra for Hemorrhagic Shock Prothrombin Complex Concentrate, Human, Placebo - Trauma Injury | Phase 2 | Unknown | Oregon Health and Science University | 166 | 2021-03-15 | 2023-12-15 |
Showing 20 of 52. Sign in to see all of them.
Shock, Septic (26) · Sepsis (16) · Cytokine Release Syndrome (12) · COVID-19 (9) · Systemic Inflammatory Response Syndrome (6) · Acquired Immunodeficiency Syndrome (3) · Respiratory Distress Syndrome (3) · Shock, Cardiogenic (3) · Shock, Hemorrhagic (3) · Acute Kidney Injury (2) · Heart Failure (2) · Infections (2) · Inflammation (2) · Multiple Organ Failure (2)
Pathological Conditions, Signs and Symptoms (52) · Pathologic Processes (51) · Inflammation (42) · Infections (38) · Systemic Inflammatory Response Syndrome (38) · Sepsis (13) · Lung Diseases (12) · RNA Virus Infections (12) · Respiratory Tract Diseases (11) · Virus Diseases (11) · Coronaviridae Infections (9) · Nidovirales Infections (9) · Pneumonia (9) · Pneumonia, Viral (9)
esmolol (5) · Saline Solution (3) · Terlipressin (3) · Angiotensin II (2) · Control Groups (2) · Hydrocortisone (2) · Methylene Blue (2) · Standard of Care (2) · Adrenergic beta-Antagonists (1) · Albumins (1) · Angiotensin I (1) · Anti-Bacterial Agents (1) · Antioxidants (1) · Ascorbic Acid (1) · Basiliximab (1)
Erasmus Medical Center (3) · Mahidol University (3) · Ain Shams University (2) · Dascena (2) · 101 Therapeutics (1) · Assaf-Harofeh Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Austin Health (1) · CHRISTUS Health (1) · Carilion Clinic (1) · Central Hospital, Nancy, France (1) · Chinese PLA General Hospital (1) · Dermama Bioteknologi Laboratorium (1) · Faculty Hospital Kralovske Vinohrady (1)
United States (8) · Egypt (5) · China (4) · Netherlands (4) · Thailand (3) · Australia (2) · France (2) · Indonesia (2) · Israel (2) · Italy (2) · Mexico (2) · Argentina (1) · Belgium (1) · Bolivia (1) · Brazil (1)
Agung Putra, Assoc.Prof (1) · Antoine Kimmoun, MD (1) · Arash Shirvani, MD, PhD (1) · Bambang Darwono, Dr.Sp.OT (1) · Bruno Levy, MD PhD (1) · Charlie Xiang, Doctor (1) · Christiaan L. Meuwese (1) · Cuthbert Simpkins, MD, FACS (1) · Daniel Azamar-Llamas, MD (1) · Davide Chiumello, MD (1) · Eric Ochoa-Hein, MD (1) · Forbes McGain, MBBS FJFICM (1)
PMID 10415784, PMID 12563677, PMID 14719037, PMID 15103422, PMID 15663512, PMID 16483293, PMID 17019126, PMID 17181919, PMID 18097874, PMID 19397687, PMID 19453649, PMID 19998041, PMID 21131395, PMID 21638157, PMID 22028728, PMID 22545014, PMID 22731679, PMID 26867177, PMID 26903338, PMID 28101605, PMID 28584818, PMID 30473697, PMID 30704260, PMID 30724734, PMID 31986264, PMID 32035018, PMID 32089354, PMID 32113509, PMID 32125455, PMID 32159775, PMID 32192578, PMID 32203186, PMID 32234467, PMID 32257537, PMID 32278362, PMID 32283152, PMID 32360286, PMID 32396163, PMID 32747157, PMID 33006765, PMID 33274176, PMID 33413583, PMID 33591006, PMID 33757717, PMID 37633275, PMID 38545092, PMID 40138463, PMID 9804346
2015 (1), K08HD052885 (1), R44AA030000 (1)